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Summary
The identification of molecular determinants of tumor
cell survival is an important objective in cancer
research. Here, we describe a small-molecule kinase
inhibitor (RGB-286147), which, besides inhibiting tu-
mor cell cycle progression, exhibits potent cytotoxic
activity toward noncycling tumor cells, but not non-
transformed quiescent fibroblasts. Extensive yeast
three-hybrid (Y3H)-based proteome/kinome scanning
with chemical dimerizers revealed CDK1/2/3/5/7/9
and the less well-characterized CDK-related kinases
(CRKs) p42/CCRK, PCTK1/3, and PFTK1 as its pre-
dominant targets. Thus, RGB-286147 is a proteome-
wide CDK/CRK-specific kinase inhibitor whose further
study could yield new insight into molecular determi-
nants of tumor cell survival. Our results also suggest
that the [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimi-
dine-4-one kinase inhibitor scaffold is a promising
template for the rational design of kinase inhibitors
with potential applications to disease indications other
than cancer, such as neurodegeneration, cardiac hy-
pertrophic growth, and AIDS.
Introduction
Cyclin-dependent kinases (CDKs) play many important
roles in cell cycle control, transcription, and the regula-
tion of cellular proliferation, apoptosis, and differentia-
tion (for reviews, see [1–4]). They exist as multiprotein
complexes, the core components being a catalytic sub-
unit (the kinase) and a regulatory subunit (the cyclin or
other regulatory protein). CDKs are active only in asso-
ciation with these regulatory partners. Besides the
cyclins, additional regulatory subunits and protein
kinases may modulate CDK activity, substrate recogni-
tion, and/or subcellular localization. For instance, vari-
ous CDK-inhibitory subunits (CKIs), such as p21Cip1/
WAF1, p15INK4b, p16INK4a, p27Kip1, and p57, regulate
the activities of CDK/cyclin complexes and can provide
tissue-specific mechanisms by which their function is
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3These authors contributed equally to this work.regulated in response to extracellular and intracellular
signals. Activation of CDKs is also regulated via post-
translational modifications by various kinases and
phosphatases [5, 6]. These include CDK-activating
kinases (CAKs) such as CDK7 and p42/CCRK [7], the
inhibitory kinases WEE1 and Myt1 [8], and the
CDC25A,B,C phosphatases.
Some of the known CDKs play a role in the regulation
of the cell cycle machinery, and they control cell cycle
progression at multiple stages of the cell cycle [1, 9].
The key cell cycle CDKs are CDK1 (CDC2), CDK2, and
CDK4/6. CDK1/cyclin B (a.k.a. mitosis promoting factor,
MPF) plays an important role in G2/M cell cycle transi-
tion, CDK4/6-D-type cyclin complexes play important
roles in integrating extracellular signals and promoting
an orderly progression through the G1 phase, and
CDK2/cyclin E or A play important roles in G1/S transi-
tion and S phase. Recent studies indicate that in certain
settings CDK2 and CDK4/6 display a relative functional
redundancy with respect to regulation of Rb phosphor-
ylation and regulation of G1/S phase transition [9]. For
example, CDK4/6 appears to be able to compensate
for the lack of CDK2 expression/activity in cultured em-
bryonic fibroblast cells and colon cancer cells [10, 11].
These findings have led to the hypothesis that CDK2
may not be a suitable target for the development of anti-
cancer agents. This conflicts with previously held con-
jectures that CDK2 plays an essential role in cell cycle
progression and survival of transformed cells [12, 13].
On the other hand, proliferation of melanoma cells has
most recently been reported to exhibit CDK2 depen-
dence [14], suggesting that chemical inhibition of CDK2
may have therapeutic benefit in the treatment of malig-
nant melanoma. Alternative functional properties of
CDKs, which are unrelated to cell cycle regulation,
include: induction of apoptosis in various cell types
(CDK1, CDK2) [15], induction of neuronal cell death
(CDK5) [3, 16], regulation of HIV1 replication (CDK9)
[17, 18], and cardiac hypertrophic growth (CDK9)
[19, 20].
An understanding of the role of CDKs in the pathogen-
esis of various diseases has stimulated an intensive
search for selective pharmacological inhibitors of these
kinases. Compounds of various chemotypes have been
described in recent years [3, 4]. Most of these low
molecular weight kinase inhibitors interact with the nu-
cleotide binding pocket of the catalytic domain of these
enzymes, thereby effectively inhibiting catalysis and
substrate phosphorylation. However, due to the struc-
tural similarity of kinase domains, these molecules can
also exhibit significant crossreactivity with other ki-
nases [4, 21], as well as with other classes of purine
binding proteins [22]. Similar observations have been
reported for other classes of kinase inhibitors. For
example, Cohen and colleagues recently showed that
many kinase inhibitors, when profiled against a larger
set of kinases, are less selective than previously recog-
nized [23, 24]. Chemical proteomics studies reported
similar findings for various serine/threonine and tyro-
sine kinase inhibitors [21, 22, 25–30]. Thus, especially
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1104Figure 1. Chemical Structures and Activity Profiles of Pyrazolopyrimidone Analogs
(A) Core structure of the [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimidine-4-one kinase inhibitor scaffold.
(B) Structure-activity profiles of pyrazolopyrimidone analogs. IC50 values for inhibition of in vitro kinase activity of purified CDKs were deter-
mined, as indicated (an asterisk indicates that flavopiridol was tested against the CDK6/D2 complex.). Alternatively, percent inhibition of
kinase activity at 0.1 mM and 1 mM compound were determined, as indicated. Inhibition of HCT116 cell proliferation after 72 hr of incubation
with compounds was determined by using the SRB assay.
(C) A model for binding of RGB-286147 in the ATP binding site of CDK2. Hydrogen bonds to the hinge region (Leu83) are shown as green lines,
the surface is colored by atom charges. The terminal hydroxy group clearly points toward solvent, suggesting a suitable site for coupling of
a PEG spacer for the synthesis of methotrexate fusion compounds (MFCs, see Figure 4).given the size of the human kinome (>500 kinases) [31],
comprehensive target profiling of kinase inhibitors re-
mains a critical issue when evaluating or validating their
mode of action (MoA), their suitability as molecular
probes, and their therapeutic potential. Driven by the
need for comprehensive small-molecule target identifi-
cation screening capabilities, chemical proteomics
initiatives have seen the emergence of various alterna-
tives to classical in vitro enzyme screening assays for
inhibitor profiling (for reviews, see [22, 32–37]). We
recently described a yeast three-hybrid system (Y3H)
for the analysis of small molecule-protein interactions
in intact cells, as well as its application to proteome-
wide screening for cellular targets of kinase inhibitors
[21, 37]. Using this approach, we have begun to system-
atically scan the proteome for targets of a number of
kinase inhibitors.
In this study, we used this approach to evaluate the
MoA of small molecules that are based on a [1, 3, 6]-
tri-substituted-pyrazolo[3,4-d]-pyrimidine-4-one kinase
inhibitor scaffold. Compounds of this chemical class
were recently described by colleagues at Bristol
Myers-Squibb and our laboratory [38]. They were shown
to be inhibitors of the cell cycle kinases CDK1 and CDK2
(and sometimes CDK4), and to exhibit potent antiproli-
ferative activity. Here, we show for a member of this
chemical class that it not only inhibits the proliferation
of many types of tumor cells, but that it also exhibits
potent cytotoxic activity toward HCT116 colon cancer
cells, irrespective of whether they are actively engaged
in cell cycle progression or not. We also find that RGB-
286147 targets kinases other than CDK1/2, although it
embodies a CDK/CRK-specific kinase inhibitor with an
apparent narrow target spectrum. We conclude that
RGB-286147 is a molecular probe suitable for investi-
gating molecular determinants of tumor cell survival
and that the [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-
pyrimidine-4-one kinase inhibitor scaffold providesa heretofore unrecognized template for the rational
design of kinase inhibitors with potentially diverse
therapeutic applications.
Results
CDK Inhibition and Antiproliferative Activity
of [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimidine-
4-one
Figures 1A and 1B summarize the chemical structures
of [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimidine-4-
one analogs used in this study; their effects on the in
vitro kinase activity of CDK1, CDK2, and CDK4/6; and
their antiproliferative activities toward HCT116 colon
cancer cells. HCT116 cells express wild-type p53 and
Rb proteins. They also express high levels of cell cycle
CDK/cyclin proteins, posing a challenge to inhibitors
of this class of kinases. Analysis of the activities of these
compounds (and various related compounds; data
not shown) suggests that the presence of a 2,6-disub-
stituted aryl group at position 1 of the [1, 3, 6]-tri-
substituted-pyrazolo[3,4-d]-pyrimidine-4-one scaffold,
combined with a small lipophilic group at position 3
and a benzyl substituent at position 6, are important
for potent CDK1/2-inhibitory activity and HCT116-anti-
proliferative activity. The presence at position 1 of an
unsubstituted phenyl group (RGB-310596) or no sub-
stituent (RGB-310595) resulted in a major loss in
CDK1/2-inhibitory activity, as well as antiproliferative
activity. Similarly, the presence at position 3 of a bulky
substituent (RGB-310591) or no substituent (RGB-
310590) resulted in a decrease in enzyme-inhibitory ac-
tivity as well as cellular activity. Analogs with various
substituents at the para position of the R3 benzyl group
generally retained potent CDK2-inhibitory and HCT116-
antiproliferative activity. Somewhat variable effects
were observed with respect to CDK1-inhibitory activ-
ity (e.g., compare RGB-286147 and RGB-286331 with
Chemical Biology of a Selective CDK/CRK Inhibitor
1105Figure 2. RGB-286147 Inhibits Cell Cycle Progression and Promotes Apoptosis
(A) RGB-286147 inhibits DNA replication, as determined by a BrdU incorporation assay.
(B) Cell cycle analysis. Cells were incubated with RGB-286147, as indicated. Control cells were treated with DMSO. Representative cell cycle
profiles are shown, with the corresponding quantifications of the percent of cells in the different phases of the cell cycle.
(C) Effects of RGB-286147 on viability of asynchronously growing HCT116 and IMR90 cells, as determined by using a Calcein AM assay
(72 hr incubation) or a clonogenic assay (24 hr drug exposure).
(D) Exposure to RGB-286147 promotes emergence of annexin-V-positive, PI-negative HCT116 cells (lower right quadrant) compared to
DMSO-treated control cells.
(E) Proteolytic cleavage of poly-ADP-ribose-polymerase (PARP) after incubation of HCT116 cells with 100 nM RGB-286147 for 48 hr.RGB-285960). CDK1/2 active compounds were generally
significantly less active against CDK4/6 (e.g., RGB-
286147). Data for flavopiridol, a known nonselective
CDK inhibitor [4], are included for comparison. In sum-
mary, significant HCT116-antiproliferative activity was
observed with compounds that also exhibited CDK1/2-
inhibitory activity. However, CDK2 is not essential for
HCT116 cells to undergo mitosis [11]. Furthermore, no
tight correlation between inhibition of CDK1 in vitro
and inhibition of HCT116 proliferation was observed,
suggesting that mechanisms other than CDK1/2 inhibi-
tion might be involved in the antiproliferative activity
of these compounds. These observations provided
the impetus to examine in more detail the cellular
activity profile of one such compound, RGB-286147,
and its potential target spectrum. Figure 1C shows
a model for binding of RGB-286147 to the active site
of CDK2. The hypothesized mechanism of enzyme
inhibition is consistent with an ATP-competitive mode
of action, as previously suggested for related analogs
[38].Cellular Activity Profile of RGB-286147: Cell Cycle
Arrest and Induction of Apoptosis
The effects of RGB-286147 on DNA replication, cell
cycle progression, and tumor cell viability are described
in Figure 2. Exposure of HCT116 cells to RGB-286147
(24/48 hr) caused a marked inhibition of DNA replica-
tion, as measured by a BrdU incorporation assay, and
effects of >80% inhibition of DNA synthesis were ob-
served at concentrations of RGB-286147 of 50–100 nM
(Figure 2A). To determine the terminal phenotype asso-
ciated with inhibition of DNA replication, a cell cycle
analysis was performed with the same effective doses
of RGB-286147 (Figure 2B). As shown, the majority of
cells in an asynchronously dividing population of
HCT116 cells were found in G1 and S phase, approxi-
mately 30% and 50%, respectively. Given that HCT116
cells divide with a doubling time of about 24 hr, reflect-
ing cell cycle transit time, cell cycle effects of RGB-
286147 were determined after 24 hr and 48 hr of incuba-
tion with RGB-286147. A pronounced accumulation of
cells in G1 phase and a significant decrease in the
Chemistry & Biology
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more, an appearance of cells with >4N DNA content
was observed at 24/48 hr with RGB-286147 at 100 nM.
At both 24 and 48 hr, a significant accumulation of
sub-G0/G1 cells had occurred, indicating the emer-
gence of a population of apoptotic cells. Perhaps sur-
prisingly, no accumulation of cells in G2/M phase was
observed. In summary, the cell cycle studies show that
RGB-286147 caused a pronounced G1 arrest, endore-
duplication, and apoptotic cell death in HCT116 cells.
Studies described below confirmed its marked effects
on cell viability and its induction of apoptotic markers.
A fluorometric Calcein AM assay was used to quanti-
tate effects of RGB-286147 on cell viability. Calcein AM
is a substrate of intracellular esterases that are active
only in viable cells. The cleavage of Calcein AM gener-
ates a fluorescent product that can be quantified on a
fluorescence plate reader. The fluorescent signal is
proportional to the number of viable cells. As shown
in Figure 2C, RGB-286147 was a potent inhibitor of
HCT116 cell viability. RGB-286147 was also found to
affect the viability of asynchronously growing, nontrans-
formed IMR90 human fibroblasts with similar potency.
Clonogenic survival assays also revealed a potent and
irreversible cell killing activity of RGB-286147 (Figure
2C). HCT116 cells were exposed to compound for
24 hr, then cultured for an additional 7 days in fresh media
without compound. The fraction of cells that retained the
ability to go through multiple rounds of cell division, and
consequently form colonies, was then determined. The
IC50 value for inhibition of colony formation by RGB-
286147 was 57 nM. In conjunction with the cell cycle anal-
ysis, these findings suggest that a 24 hr exposure of
HCT116 cells is sufficient to promote an irreversible,
albeit delayed, cell death. RGB-286147 was more potent
in this assay than flavopiridol. Exposure to RGB-286147
also induced an increase in annexin-V-positive cells
(Figure 2D), a hallmark of apoptosis. Similarly, an increase
in TUNEL-positive cells (as determined with a Terminal
deoxynucleotidyl transferase dUTP Nick End Labeling
assay) was observed upon exposure of HCT116 cells
to RGB-286147 (data not shown). Exposure of HCT116
cells to RGB-286147 resulted in proteolytic cleavage of
poly-ADP-ribose-polymerase (PARP), a known substrate
for the caspase-3 apoptotic protease (Figure 2E); this
finding is also consistent with an induction of apoptosis.
RGB-286147 Is a Broad-Spectrum Inhibitor
of Tumor Cell Proliferation
The studies described above identified RGB-286147 as
a potent inhibitor of cell cycle progression and the sur-
vival of HCT116 colon cancer cells. Here, we examined
its activity profile across a broad panel of tumor cells of
various genetic backgrounds and tissue origins. The
Developmental Therapeutics program of the National
Cancer Institute (NCI, US) provides a screening program
through which compounds can be evaluated in a panel
of 60 tumorigenic cell lines. This panel consists of cell
lines expressing wild-type or mutant p53, p16-deficient
and Rb mutant cell lines, and cell lines with various
other genetic aberrations, including multidrug resis-
tance. RGB-286147 was evaluated in this panel by the
NCI and was found to be a highly potent and broad-
spectrum inhibitor of tumor cell growth (Appendix S1;see the Supplemental Data available with this article on-
line). The average GI50 for RGB-286147 at 48 hr of
exposure was less than 10 nM. Interestingly, the GI50
value for the adriamycin/multidrug-resistant cell line
NCI/ADR-RES was also less than 10 nM (with a TGI of
32–70 nM). Furthermore, the GI50 for the Rb-deficient
prostate cancer cell line DU-145 was also less than
10 nM. Collectively, these results indicate that RGB-
286147 is not subject to P-glycoprotein-mediated drug
efflux, and that it is active against tumor cells with a va-
riety of genetic aberrations, including Rb-deficient cells.
RGB-286147 Induces Cell Death in Noncycling
HCT116 Tumor Cells
The proliferation of nontransformed, diploid cells, such
as IMR90 human fibroblasts, requires the presence of
growth factors, the removal of which leads to a decrease
in cellular CDK activity and consequent exit from the cell
cycle. Thus, as expected, serum withdrawal led to cell
cycle arrest of cultured IMR90 cells, as measured
by the BrdU incorporation assay (Figure 3A). HCT116
tumor cells also underwent cell cycle arrest in response
to serum withdrawal. Most importantly, these effects
were reversible. This was determined by a SNARF-1
viability assay (Figure 3A), a trypan-blue exclusion as-
say (data not shown), as well as a clonogenic assay. In
the clonogenic assay, cells were cultured in the absence
of serum for 6 days, trypsinized, collected, and replated
in complete media (1FCS). More than 80% of the plated
cells were capable of colony formation, indicating that
serum-starved HCT116 cells were indeed in a state of
reversible cell cycle arrest (the typical plating efficien-
cies of nonstarved cells would be similar). These obser-
vations allowed for an assessment of the effects of
RGB-286147 on the viability of cell cycle-arrested cells
as opposed to proliferating cells.
As shown in Figure 3B, RGB-286147 was equally
active against noncycling as proliferating HCT116 cells.
Similar results were obtained with several other com-
pounds of this class (data not shown), as well as with
flavopiridol. In contrast to flavopiridol, however, RGB-
286147 was significantly less active toward quiescent
versus proliferating IMR90 fibroblasts (more than 1–2 or-
ders of magnitude less potent. Such observations were
also made with several other related compounds; data
not shown.). Exposure of arrested HCT116 cells to
RGB-286147 also inhibited their ability to form colonies
subsequent to refeeding with serum-supplemented cul-
ture medium. HCT116 cells were serum starved for
6 days and then exposed to RGB-286147 for 4 or 24 hr.
Colony formation was assessed after an additional 5
days of growth in complete media. We observed a time-
and dose-dependent loss of colony formation ability fol-
lowing exposure to RGB-286147 (Figure 3C). The untreat-
ed, serum-starved cells formed colonies upon refeeding
with the same efficiency as nonstarved control cells
maintained in complete media. Taken together, these
results indicate that RGB-286147 inhibits the viability
of HCT116 cells in the absence of cell cycle progression.
Target Profile of RGB-286147: Y3H-Based
Proteome and Kinome Scanning
The cell cycle effects of RGB-286147, as well as its
effects on the survival of both cycling and noncycling
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than (or in addition to) CDK1 and CDK2. The following
points support this supposition. First, it has been shown
that CDK2 is not required for proliferation of various
colon cancer cells, including HCT116 cells [11], and we
have similarly found that CDK2-siRNA-induced down-
regulation of CDK2 does not inhibit proliferation of these
cells (data not shown). However, we did find that RGB-
286147 caused a pronounced G1 arrest (Figure 2B).
Second, RGB-286147 induced endoreduplication, as in-
dicated by the emergence of cells with >4N DNA con-
tent (see Figure 2B). Endoreduplicators are prone to
undergo apoptotic cell death, and this could explain
the emergence of the sub-G0/G1 cell population. It
has been reported that inhibition of CDK1 renders fis-
sion yeast cells prone to chromosomal reduplication
[39]. So, in principle, inhibition of CDK1 could have sim-
ilar effects in mammalian cells. However, no accumula-
tion of cells in G2/M was observed with RGB-286147,
raising the question: is CDK1 actually inhibited by
Figure 3. RGB-186147 Promotes Tumor Cell Death in the Absence
of Cell Cycle Progression
(A) Serum starvation (2FCS) causes inhibition of DNA replication in
HCT116 cells and IMR90 fibroblasts, as determined by BrdU incor-
poration. Arrested cells remain viable, as determined by a SNARF-1
assay.
(B) RGB-286147 promotes cell death in proliferating (1FCS) and
noncycling (2FCS) HCT116 cells (72 hr exposure). In contrast,
RGB-286147 promotes cell death in proliferating, but not arrested,
IMR90 cells. Effects of flavopiridol are also shown. Effects on viabil-
ity of cells were determined by the Calcein AM assay. Calculated
IC50 values for loss of viability in response to the various treatments
are shown.
(C) Percent inhibition of colony formation by serum-starved
HCT116 cells treated with RGB-286147. Cells were plated and se-
rum starved for 6 days, exposed to the compound for the indicated
period, and refed with complete media. Colony number was nor-
malized to that obtained with untreated control cells also refed with
complete media.RGB-286147 (at 50–100 nM) to a significant extent in
intact cells? It is also noteworthy that compounds that
were less active than RGB-286147 toward CDK1 in vitro,
such as RGB-285960 (IC50: 310 nM), were as potent
as RGB-286147 in inhibiting HCT116 proliferation (see
Figure 1) and viability (IC50 for RGB-285960: 15 nM).
These observations raise further doubt regarding the
extent to which inhibition of CDK1 might have been im-
plicated in the cytotoxic effects of RGB-286147.
Based on these considerations, we initiated a search
for alternative targets of RGB-286147 by using the Y3H-
based screening approaches we recently described
[21]. The basic concept of the Y3H assay used in this
study is briefly described in Figure 4A. As described
previously, methotrexate-based hybrid ligands (metho-
trexate fusion compounds, MFCs) were used. SAR in-
formation that was available to us (e.g., as described
in Figure 1), as well as the structural model highlighted
in Figure 1C, suggested that positioning a polyethylene-
glycol (PEG) spacer at the para position of the 6-benzyl
substituent of RGB-286147 would not interfere with its
inhibition of CDKs (and possibly other candidate
kinases). As predicted, RGB-286276, a PEGylated ana-
log of RGB-286147, retained CDK1- and CDK2-inhibitory
activity as well as cellular activity (Figure 4B). Thus, two
MFC derivatives of RGB-286147, RGB-286580 and a
trichloro derivative, RGB-286156 (Figure 4C), were
synthesized according to this strategy, which was
described previously [21]. Both MFCs were assayed
for yeast cell uptake and binding to DHFR by using an
MFC competition assay (Figure 4D, see also Experimen-
tal Procedures for details). As shown, both test MFCs,
RGB-286580 and RGB-286156, were found to permeate
the yeast cells and bind to DHFR. Therefore, they pro-
vided suitable ‘‘baits’’ for screening and identification
of target proteins. Two Y3H screening strategies were
pursued: (1) random screening of human AD-cDNA
libraries [21], which could lead to the identification of
diverse target proteins (i.e., kinase and non-kinase tar-
gets); and (2) direct screening of robotically generated
replica arrays of transformed yeast cells expressing in-
dividually cloned kinases/kinase domains (each array
coordinate representing one specific kinase), many of
which were previously found to interact with one or
another small-molecule kinase inhibitor (approximately
250 such ‘‘functional’’ kinases, including S/T- and
Y-kinases; data not shown). A total of approximately
500 cloned human kinases were represented in these
yeast arrays (details of this clone collection will be pub-
lished elsewhere). RGB-286512, a ‘‘universal’’ control
that consists of MTX linked to the PEG spacer
(MTX-PEG), and MTX-DEX, which consists of MTX
linked to dexamethasone (DEX), were used as control
compounds.
Figure 5A summarizes the Y3H screening results. For
comparison, results obtained with RGB-286076, a pur-
valanol B-MFC we described earlier [21], were included.
Several targets were identified, all of which encoded
kinases. These included CDK1 (the weak signal is pre-
sumably due to the very weak expression of CDK1 in
yeast; data not shown), CDK2, CDK3, CDK4, CDK5,
and CDK6. Additional CDKs/CRKs included: CDK9,
p42/CCRK (a CDK2-CAK), PCTK1 and PCTK3 (possi-
bly PCTK2, although a comparably weak signal was
Chemistry & Biology
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(A) Schematic representation of the Y3H system.
(B) A PEGylated derivative of RGB-286147 (RGB-286276) retains
CDK-inhibitory activity and inhibits HCT116 cell proliferation and
viability (Calcein AM assay).
(C) Chemical structures of methotrexate-based chemical dimer-
izers (methotrexate fusion compounds, MFCs).detected, in particular, when compared to that observed
for other kinase inhibitors; see [21]), and PFTK1. GSK3A
represents a non-CRK kinase. Representative examples
of ‘‘no hits,’’ such as CSNK1D, E, LCK, FYN, and YES1,
are also shown in Figure 5A; these, in contrast, scored
positively with the purvalanol B-MFC (we have pre-
viously shown that purvalanol B also inhibits the enzyme
activity of these kinases in vitro [21]). Similarly, RGB-
286580 and RGB-286156 did not interact with several
hundreds of other kinases that were part of the kinase
array (data not shown). In contrast, the MFC incorporat-
ing purvalanol B, a purine analog and known CDK inhib-
itor, scored positively with a broad range of kinases
other than CDKs (see also reference [21]), only a subset
of which are shown in Figure 5A. A broad target spec-
trum was recently also described for yet another type
of potent CDK inhibitor belonging to the chemical class
of indenopyrazoles [21]. Thus, in comparison, the com-
pounds described here display a remarkable specificity
for CDK/CRK kinases in Y3H.
In order to validate the interactions identified with
Y3H, in vitro small molecule-protein binding assays
were performed. A PEGylated affinity chromatography
probe, RGB-286051, was directly coupled to solid
phase, as previously described [21]. Bead-immobilized
compound was then incubated with cell extracts to
determine its ability to bind to either endogenous or
myc-tagged versions of the candidate targets. Bound
proteins were eluted and subjected to immunoblot anal-
ysis (Figure 5B). For the detection of the binding of
endogenous proteins to compound, cellular extracts
derived from Jurkat, HCT116, or HEK293 cells were
used. Extracts derived from transiently transfected
HEK293 cells were used to detect binding of myc-
tagged kinases/kinase domains by using an anti-myc
tag antibody in the immunoblot analysis. As shown,
specific binding to immobilized RGB-296051 was de-
tected for endogenous CDK1, -2, -5, -7, and CDK9. Cu-
riously, no binding for myc-tagged CDK9 was observed,
the reason for which remains unclear. In addition, spe-
cific binding was observed for the myc-tagged forms
of p42/CCRK, PCTK1, and PCTK3. In summary, the re-
sults described in Figure 5 suggest that RGB-286147
and related pyrazolopyrimidones exhibit a preferential
affinity across the proteome for a relatively small group
of CDK/CRK kinases.
Selectivity Profiling of RGB-286147: In Vitro
Kinase Assays
RGB-286147 was profiled for activity against a panel of
69 recombinant kinases (Upstate) to further examine its
selectivity profile (Figure 6A). Inhibitory effects on in
(D) Methotrexate and MFCs permeate yeast cells and prevent bind-
ing of a test peptide-AD fusion protein to DHFR. This 16-mer
peptide was identified on the basis of its ability to bind DHFR
in a methotrexate-sensitive fashion, providing an assay system
for MFC competition experiments, as shown. Inhibition of the peptide-
DHFR interaction, and consequently inhibition of HIS3 reporter
activation, is reflected in a decrease in growth of yeast cells in the
absence of histidine in the culture medium. Inhibition of growth in
response to increasing concentrations of test MFCs is shown (error
bars indicate standard deviations from the mean, n 5 3 indepen-
dent experiments).
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Y3H Proteome Screening
(A) Y3H pyrazolopyrimidone MFC-target
interactions. Interactions were originally iden-
tified via cDNA library screening (indicated
by ‘‘screen hit’’ annotation) or direct screen-
ing of arrays of yeast cells transformed with
individually cloned kinases. cDNA clones
identified by the cDNA library screening ap-
proach were also used to retransform yeast
cells and were subjected to array-based
screening, as shown. A positive interaction
is reflected in positive yeast cell growth
(activation of HIS3 reporter). Arrays were
interrogated with the indicated MFCs and
a MTX-PEG ‘‘universal control.’’ Images from
each 96-well format array screen (one com-
pound per array) were clustered to yield the
composite image shown here.
(B) In vitro binding of endogenous proteins
(Jurkat [CDK1, CDK2, CDK5], HCT116
[CDK7], or HEK293 cells [CDK9]) and exoge-
nous, myc-tagged proteins (expressed in
HEK293 cells) to a bead-immobilized pyrazo-
lopyrimidone test compound, RGB-286051,
or beads coupled to PEG spacer alone,
RGB-286792. Protein binding was detected
by immunoblot analysis with antibodies
directed against endogenous proteins or
the myc tag of the transgene-encoded fusion
proteins, as indicated.vitro kinase activity were first determined at a concen-
tration of compound of 1 mM. As shown, 8 out of 69
kinases that were evaluated scored positive (R50%
inhibition). IC50 values were subsequently determined
for these particular kinases (Figure 6B). In addition to
potently inhibiting CDK1 and CDK2, RGB-286147 in-
hibited the kinase activity of CDK3, CDK5, and CDK7,
with similar potency (low nanomolar IC50 values). Com-
paratively, RGB-286147 only weakly inhibited CDK4,
CDK6, and GSK3b (higher nM–mM range IC50 values).
CDK9 IP-kinase assays confirmed that RGB-286147
is also a potent inhibitor of cellular CDK9 (Figure 6C).
The effects of RGB-286147 were compared to those of
flavopiridol, a reportedly potent CDK9 inhibitor [40, 41]
(reported IC50 for CDK9 inhibition: 5–10 nM). Bothcompounds inhibited the autophosphorylation of
CDK9 as well as the crossphosphorylation of cyclin T1
by CDK9 in a dose-dependent manner and with compa-
rable potency. Similar effects were observed when
assaying the phosphorylation of the C-terminal domain
(CTD) of RNA pol II, a natural substrate for CDK9. The
relative activity of RGB-286147 toward CCRK and the
PCTKs remains to be determined. In summary, the re-
sults described in Figures 6 and 7 further suggest that
RGB-286147 and related analogs exhibit a high degree
of specificity for CDK/CRK kinases.
Inhibition of CDKs by RGB-286147 in Intact Cells
A common view is that phosphorylation of Rb is trig-
gered by CDK4/6 kinases and probably completed by
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(A) Inhibition of in vitro kinase activity of
purified kinases by RGB-286147. Percent
inhibition at 1 mM compound is shown.
(B) IC50 values for inhibition of kinase activity
by RGB-286147.
(C) Inhibition of CDK9 kinase activity by
RGB-286147. CDK9 IP-kinase assays were
performed, as indicated, measuring either
CDK9 autophosphorylation and cyclin T1
crossphosphorylation (upper panel) or phos-
phorylation of purified CTD3 (C-terminal
domain of RNA ploymerase II, a natural
substrate of CDK9, lower panel). The total
amount of cyclin T1 in each immunoprecipi-
tate was also determined by immunoblotting
in order to control for the potential difference
in sample loading. WB: Western blot analysis
for cyclin T1 and/or CDK9, as indicated.CDK2 as cells enter S phase. Here, we assessed the
effects of RGB-286147 on the phosphorylation status of
Rb, as well as other cell cycle regulatory proteins (Figure
7). As expected for a compound that promotes G1
arrest and a decrease in the number of cells in S phase,
RGB-286147 caused a significant reduction in cyclin A
expression. RGB-286147 also caused a reduction in
phosphorylation of Rb on Ser807/811 (CDK2 phosphor-
ylation sites) as well as Ser795 and Ser780 (CDK4 phos-
phorylation sites), suggesting that RGB-286147 inhibits
the activity of CDK4/6, and perhaps that of CDK2, in
cells. Recent observations made by Tetsu and McCor-
mick [11] indicate that inhibition of CDK4/6, but not
CDK2, reduces phosphorylation of Rb at Ser807/811
in HCT116 cells. They hypothesized that the unusually
high level of CDK4/6 activity in these cells, due to loss
of p16/INK4a, upregulation of cyclin D1 (through Ras
and b-catenin), and expression of the assembly factor
p21/Cip1, was sufficient to promote crossphosphory-
lation and make CDK2 redundant. Accordingly, the
decrease in Ser807/811 phosphorylation caused by
RGB-286147 was more likely due to inhibition of
CDK4/6. CDK4/6 was not strongly inhibited by RGB-
286147 in vitro. However, RGB-286147 caused a marked
reduction in cyclin D1 levels, an effect known to result in
a decrease in CDK4 activity in HCT116 cells [11].Analysis of the phosphorylation status of CDK2
showed that RGB-286147 also caused a significant
decrease in the levels of the p-Thr160-phosphorylated
form of CDK2. Phosphorylation of CDK2 at Thr160 is re-
quired for its activation [6]. CDK7 and CCRK [7], which
have been shown to exhibit CDK2-activating activity,
were both found to be targets for RGB-286147. Thus,
inhibition of one or both of these kinases may contribute
to the overall effects of RGB-286147 on CDK2 activa-
tion. CDK7 also exhibits CDK1/4-activating activity. It
remains unclear, however, whether RGB-286147 also
had an effect on activation of these kinases. Whether
CDK4/6 is a substrate for CCRK is also unclear. In sum-
mary, RGB-286147 caused a significant inhibition of
CDK2 and CDK4/6 activity in HCT116 cells. Inhibition
of CDK4/6 in HCT116 cells is sufficient to cause G1
arrest and inhibition of proliferation of HCT116 cells
[11, 42]. Thus, indirect inhibition of CDK4/6 provides
one plausible mechanism for the G1 arrest induced by
RGB-286147 in HCT116 cells.
Discussion
In the present study, we undertook a first step toward
a more detailed analysis of the pharmacological proper-
ties and therapeutic potential of compounds that are
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midine-4-one CDK kinase inhibitor scaffold. Com-
pounds of this class were recently shown to inhibit the
in vitro kinase activity of CDK1 and CDK2 [38], but the
molecular basis for their antiproliferative and antitumor
activities remained unclear. Our analysis of related ana-
logs, such as RGB-286147, indicates that compounds
of this chemical class can exhibit a more complex range
of antitumor activities than previously recognized, and
that these activities involve targets in addition to or
other than CDK1 and CDK2. The cell killing activity of
RGB-286147 in noncycling HCT116 colon cancer cells,
but not in quiescent nontransformed fibroblasts, is par-
ticularly intriguing and suggests that exploring the MoA
of this compound and related analogs could yield new
insights into mechanisms regulating the survival of
tumor cells that are not actively engaged in cell cycle
progression.
The HCT116-antiproliferative activities of RGB-
286147 are reflected in a pronounced decrease in the
number of S phase cells and a concomitant accumula-
tion of cells in G1 phase of the cell cycle. Although
RGB-286147 appears to inhibit CDK2 in HCT116 colon
cancer cells, the G1 cell cycle-inhibitory effect appears
to be mediated through an inhibition of CDK4. RGB-
286147 is not a potent inhibitor of purified CDK4/cyclin
D1 (or CDK6/cyclin D3). However, in cells, RGB-
286147 caused a decrease in the expression of cyclin
D1, one of its regulatory components, an effect known
to result in a decrease in CDK4 activity in HCT116 cells
[11]. Whether CDK4/6 could also be inhibited by other
mechanisms remains to be explored. Inhibition of
CDK7 by RGB-286147 could possibly interfere with
the activation of CDK4/6 [6]. Another interesting possi-
bility may involve the CDK-activating kinase p42/
CCRK. This kinase has recently been reported to act
as a CDK2 (but not CDK1)-activating kinase [7]. CDK2
activation appears to be inhibited by RGB-286147,
which could have involved inhibition of p42/CCRK.
Furthermore, interference with p42/CCRK activity or
expression has recently been reported to cause a G1
cell cycle arrest in HeLa cells [7], which, similar to
Figure 7. Effects of RGB-286147 on Cell Cycle Regulatory Proteins
in Intact Cells
Effects of RGB-286147 on the expression levels of various cell
cycle regulatory proteins (cyclin A, cyclin D1, CDK2) and phosphor-
ylated forms of Rb and CDK2. HCT116 cells were incubated for 24
hr (100 nM RGB-286147) prior to analysis by immunoblotting with
antibodies specific for the respective protein/phosphoproteins.HCT116 colon cancer cells, do not appear to require
CDK2 for cell cycle progression [11]. Therefore, it is con-
ceivable that RGB-286147 induces G1 arrest in HCT116
cells through inhibition of p42/CCRK and substrates
other than CDK2. A further clarification of the effects
of RGB-286147, and related analogs, on p42/CCRK in
cells may facilitate the functional characterization of
this interesting kinase.
Besides perturbing cell cycle progression, we also
found RGB-286147 to induce a pronounced apoptotic
cell death in HCT116 colon cancer cells. RGB-286147
was also active against cell cycle-arrested HCT116
cells. In contrast, RGB-286147 inhibited the prolifera-
tion and viability of nontransformed human fibroblasts
(IMR90 cells), but was inactive toward these cells
when in the quiescent state. Only a limited number of
cancer cells in established tumors do cycle at any point
in time, which poses a problem for many chemothera-
peutic drugs that are primarily active against cycling
tumor cells. Gaining insights into mechanisms that reg-
ulate the survival of noncycling tumor cells could lead to
new drug discovery strategies. RGB-286147 provides
a promising molecular probe for such investigations. In-
hibition of CDK1, CDK2, or CDK4 is not likely to play
a major role in the cytotoxic effects of RGB-286147 in
serum-starved/non-cycling HCT116 cells, as it is pre-
sumed that, in these cells, these kinases are in an inac-
tive state. This supposition is also supported by the
recent findings that highly selective small-molecule in-
hibitors of CDK4/6 induce a reversible G1 arrest in the
Rb-positive HCT116 cells while having no effect on
Rb-negative tumor cells [11, 42]. Furthermore, as
already discussed, neither CDK2 nor CDK1 are likely
to be the sole or primary mediators of the cytotoxic
effects of RGB-286147 in cycling HCT116 cells. On the
other hand, the proteome profiling efforts described
here reveal a first set of candidate targets that could
be investigated in this context. RGB-286147 targets
that we identified include: CDK3, CDK5, CDK7, CDK9,
p42/CCRK, PCTK1/3, and PFTK1. CDK3 has been re-
ported to play a role in promoting G0 exit [43], and
mice develop normally in the absence of functional
CDK3 [44]. CDK5 has been linked primarily to neuronal
and secretory cell functions [4, 15]. Thus, neither of
these kinases is a likely mediator of the cytotoxic acti-
vites of RGB-286147, and future studies should argu-
ably focus on the remaining kinases, the functions of
some of which are currently only poorly understood.
The finding that RGB-286147 and its derivatives ex-
hibit a highly specific and arguably narrow CDK/CRK
target profile should facilitate the design and charac-
terization of novel analogs with subtle differences in
selectivity profiles. We have recently indeed identified
analogs that exhibit significant differences in their
CDK selectivity profiles (unpublished data). For exam-
ple, compounds with higher selectivity for CDK5 or
CDK9 could have therapeutic applications in indications
other than cancer. CDK5 plays a role in neuronal and se-
cretory cell functions and has emerged as an interesting
candidate target for inhibition of neuronal cell death.
CDK9 has recently been implicated in the pathogenesis
of cardiac hypertrophic growth and as a permissive host
factor in HIV-1 replication [17]. Roscovitine (or CYC202),
a reported CDK1/2/5/7/9 inhibitor, has recently been
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transcription, and to induce apoptosis in HIV-1-infected
cells, an effect not observed in uninfected control cells
[45]. This and other studies [17, 18] suggest that inhibi-
tion of CDK9 could be a strategy for the development
of a novel generation of AIDS therapeutics. Thus, the ob-
servation that [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-
pyrimidine-4-one analogs exhibit potent CDK5- and
CDK9 kinase-inhibitory activities, while targeting a nar-
row spectrum of CDKs/CRKs (compared to other CDK
inhibitor chemotypes [21]), suggests that this chemical
class should be further examined for the design of
novel, potentially even more selective kinase inhibitors
with applications to therapeutic areas other than can-
cer. Finally, this study further highlights the utility of
Y3H screening in drug MoA studies. We anticipate that
Y3H screening will prove to be generally useful in the
identification of targets for various kinase inhibitor che-
motypes, as well as other classes of organic small
molecules.
Significance
The realization that small-molecule inhibitors of pro-
tein kinases might be of therapeutic use, as exempli-
fied by the use of phenylaminopyrimidine STI571
(also known as imatinib mesylate or Gleevec) in the
treatment of chronic myelogenous leukemia, has led
to intensive drug discovery efforts around multiple
disease-relevant kinases. These include the subfamily
of cyclin-dependent kinases (CDKs) and CDK-related
(CRK) kinases. Due to the potential of ATP-competi-
tive kinase inhibitors to crossreact with multiple,
even phylogenetically distantly related, kinases, iden-
tifying their targets is a critical challenge in validating
their use as potential therapeutic agents or as molec-
ular probes. Here, we used a chemical proteomics
approach to explore the mechanisms of action and
potential applications of compounds derived from
a [1, 3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimidine-4-
one kinase inhibitor scaffold. Our results suggest that
this class of compounds exhibits a remarkable speci-
ficity for kinases of the CDK/CRK subfamily of protein
kinases, and a source of novel molecular probes for
exploring mechanisms that regulate tumor cell
survival in the presence and/or absence of cell cycle
progression. Our results also suggest that the [1,
3, 6]-tri-substituted-pyrazolo[3,4-d]-pyrimidine-4-one
scaffoldmay be further exploited for the design of pro-
teome-wide CDK/CRK-specific kinase inhibitors with
various therapeutic applications. Finally, this study
further highlights the potential for Y3H in the identifi-
cation of novel kinase inhibitor targets. Y3H should
be equally applicable to the study of other types of
organic small molecules.
Experimental Procedures
Compound Synthesis
Details of an example MFC synthesis (RGB-286580) are provided
in the Supplemental Data (Appendix S2). The other [1, 3, 6]-tri-
substituted-pyrazolo[3,4-d]-pyrimidine-4-one analogs were synthe-
sized by procedures similar to the synthesis of Compound 1 in
Appendix S2.Molecular Modeling
Using program FlexX [46], the inhibitor RGB-286147 was docked
into the ATP binding site of CDK2 (PDB entry 1ckp). A 6.5 A˚ distance
cut-off for the ATP binding site was applied; water and inhibitor
molecules were excluded from the calculation. The model that was
obtained is in agreement with the recently published X-ray structure
of CDK2 in complex with a comparable pyrazolo-pyrimidin-4-one
compound [38]. The picture was rendered with ViewerPro
(Accelsys) and Povray (http://www.povray.org).
In Vitro Kinase Assays
CDK kinases and cyclins were expressed in Sf9 insect cells. CDK/
cyclin complexes were purified and assayed as described previ-
ously [47]. Alternatively, the effects of compounds on kinase activity
were tested at Upstate Biotechnology.
Cell Culture and Viability Assays
HCT116 colon carcinoma cells (ATCC) were grown in RPMI-1640
supplemented with 10% FCS in a humidified incubator at 37ºC
and 5% CO2. Viability was measured in a 24-well format (1,000 cells
per well) with the Calcein AM assay (Molecular Probes). The fluores-
cent, viable cells were quantitated with a Cytofluor II fluorescent
plate reader (PE Biosystems). The clonogenic survival of cells
treated with RGB-286147 was determined by treating 10,000 cells
grown in 15 cm plates with the compound for 24 hr, followed by
a 7 day outgrowth in media without compound. Colony number
was determined by manual counting of cells stained with 0.4% crys-
tal violet in 20% ethanol. Cellular proliferation was determined with
the Sulforhodamine B (SRB) assay [48]. HCT116 cells were grown in
96-well microtiter plates (1,000 cells/well) and were exposed to the
compounds for 72 hr. The cells were fixed with cold TCA to a final
concentration of 10% and incubated at 4ºC for 60 min. The plates
were then washed five times with water and air dried. SRB solution
at 0.4% (w/v) in 1% acetic acid was added to each well, and the
plates were incubated for 10 min at room temperature. The plates
were washed five times with 1% acetic acid and air dried. The
bound stain was then solubilized with 10 mM trizma base, and the
absorbance was read on a plate reader at 570 nM.
Cell Cycle Analysis
HCT116 cells were harvested from subconfluent plates, and
100,000 cells were treated with a range of doses of RGB-286147
for 24 or 48 hr. At the indicated time, the adherent cells were recov-
ered by trypsinization, combined with the floaters, and collected
by centrifugation. Medium was decanted from the cell pellet, and
100 ml PI stain-1, which contains 50 mg/ml propidium iodide, 3%
PEG 6000, 180 U/ml RNase, 0.1% Triton-X, 3.6 mM citrate buffer
(pH 7.2), was added to the cell pellet. The cells were incubated at
37ºC for 20 min, after which 100 ml PI stain-2, which contains 3%
PEG 6000, 50 mg/ml propidium iodide, 0.1% Triton-X, and 0.375 M
NaCl (pH 7.2), was added to the cells. The cells were incubated at
4ºC for 1 hr and analyzed on a Becton Dickenson FACScan flow
cytometer fitted with ModFit LT cell cycle analysis software (Verity
Software House, Inc.). The effect of RGB-286147 on DNA replication
was measured with BrdU in a flow cytometric assay. HCT116 cells
(100,000 cells /T-25 flask) were cultured in the presence of RGB-
286147 for a period of 24 or 48 hr before the addition of BrdU
(10 mM final concentration), after which the incubation was contin-
ued for 16–18 hr. Incorporation of BrdU was determined with the
BrdU Flow Kit (BD-Pharmingen) according to the manufacturer’s
specifications and was quantified on the flow cytometer.
Analysis of Apoptosis
HCT116 cells (1 3 105 per T75 flask) were treated with 50 nM RGB-
286147 for 48 hr. The cells were recovered by trypsinization, were
incubated with a buffer containing AnnexinV-FITC and propidium
iodide according to the manufacturer’s specification (BD Pharmin-
gen #556547), and were analyzed by flow cytometry.
Arrested Cell Assay
The cytotoxicity of RGB-286147 was determined on arrested normal
fibroblasts, IMR90, and tumorigenic cells, HCT116. IMR90 cells
were plated in triplicate for each compound concentration to be
tested in MEM-a media containing 10% fetal calf serum at a density
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cubated overnight at 37ºC, 5% CO2. The media was replaced from
the 20,000 cells per well dish with serum-free media after washing
once with the same, while the wells containing 2,000 cells were
maintained in complete media. The plates were incubated for 3 ad-
ditional days. HCT116 cells were plated in triplicate for each com-
pound concentration to be tested in RPMI 1640 media containing
10% fetal calf serum at a density of either 200 or 2,000 cells per
well in 24-well dishes and were incubated overnight at 37ºC, 5%
CO2. The media from the 2,000 cells per well dish were replaced
with serum-free media after washing once with the same. It had
been established in a prior experiment that the HCT116 cells re-
quired 6 days to arrest in response to serum starvation, so the
plates were incubated for this period of time. The cells were ex-
posed to a dose range of RGB-286147 for 72 hr in the absence of
serum, and the effect on viability was determined with the Calcein
AM assay as described above. In order to ensure that the cells
had indeed exited the cell cycle upon serum withdrawal, the per-
centage of BrdU-positive cells was determined in each experiment.
In these experiments, cellular viability and cell cycle progression
were evaluated simultaneously by flow cytometry. For this purpose,
cell viability was determined with the use of SNARF-1, a red fluores-
cent alternative to Calcein. With this method, cells can be costained
with FITC (green fluorescence) to detect BrdU and SNARF-1 (red
fluorescence) to measure viability. Together, the evaluation of
BrdU incorporation and SNARF-1 cleavage by flow cytometry pro-
vides an assessment of the viability of arrested cells. The cells
were stained with SNARF-1 as follows and then prepared for deter-
mination of BrdU incorporation as described above. A 5 mg/ml solu-
tion of SNARF-1 (Molecular Probes) was prepared by dissolving 50
mg SNARF-1 in 50 ml DMSO and dilution into 10 ml PBS. This stock
was further diluted 1:64,000, and 200 ml was added to each tube of
cells that had been previously pulsed with BrdU. The cells were
incubated at 37ºC for 30 min and washed with 3 ml PBS. The cells
were then fixed and prepared for the measurement of BrdU as
described above.
Bacterial and Yeast Strains
E. coli strain DH10B (Life Technologies) was used for all bacterial
work in this study. The Saccharomyces cerevisiae strain used in
this study was strain 6A (GPC Biotech AG; MATa, his3-D200, trp1-
901, leu2-3,112, LYS2::[4lexAopHIS3], ade2::[6lexAopURA3],
ura3::[8lexAopLacZ], GAL4, gal80, can1, cyh2). The strain enables
the use of a LexA binding domain-based protein interaction
systems using the HIS3 and/or LacZ reporters and the use of
cDNA libraries fused to the GAL4p activation domain (AD). Yeast
cells were grown in synthetic dextrose (SD) media with appropriate
auxotrophic supplements [49]. Standard genetic methods were
followed.
Plasmids
Plasmid pBYK-DHFR was described before [21]. A variant of pACT2
(Clontech), which was compatible for use with the GATEWAY in vitro
recombination cloning system (Invitrogen), was generated and used
for directional cloning of cDNAs encoding specific kinases.
Competition Experiments
We previously identified a 16-mer peptide (RLGSPSGVLDMYCRLH)-
AD fusion that interacts with DHFR. Binding of methotrexate to
DHFR prevents this interaction. Similarly, binding of an MFC to
DHFR interferes with this interaction. Thus, the successful uptake
of an MFC into yeast and its binding to DHFR can be measured as
a function of a decrease in HIS3 reporter activity (reflected in
dose-dependent inhibition of cell growth) induced by expression
of the peptide-AD fusion protein and LexA-DHFR. To test for growth
competition, either 1 ml DMSO (negative control, 100% growth) or
1 ml test MFC at an appropriate concentration was added. Yeast
cell growth was monitored and quantified by measuring the optical
density of the culture at day three at a wavelength of 600 nm.
cDNA Libraries
Strain 6A 1 pBYK-DHFR was transformed by using the lithium
acetate method [37]. pACT2-based cDNA libraries were purchased
from Clontech: human brain, liver, heart, and placenta. All librariesencoded polypeptides fused to the carboxy terminus of the GAL4
activation domain. The total number of independent yeast colonies
reflected at least 13 the complexity of independent clones docu-
mented for the E. coli library, as specified by the manufacturer.
The yeast libraries were harvested, quality control tested, and
stored in small aliquots at 270ºC.
cDNA Library Screening and Array Screening
The screening of cDNA libraries and kinase arrays with RGB-286580
and RGB-286156 was performed as described previously [21].
RGB-286580 exhibited some autoactivating activity. This could be
easily suppressed by the addition of 10 mM 3-amino-1,2,4-triazole.
Binding of RGB-286051 to Kinase Targets In Vitro
A PEGylated pyrazolopyrimidone CDK inhibitor (RGB-286051) or a 5
PEG-amine linker (RGB-286792) was coupled to ReactiGel agarose
beads (Pierce, No. 20259) as previously described [28]. Pull-downs
were essentially performed as previously described [28]. In vitro
binding of endogenous proteins was detected by using extracts
of Jurkat (CDK1, CDK2, CDK5), HCT116 (CDK7), or HEK293 cells
(CDK9). Exogenous myc-tagged proteins were expressed in
HEK293 cells. Protein binding was detected by immunoblot analysis
with antibodies directed against endogenous proteins or the myc
tag of transgene-encoded fusion proteins, as indicated. Immobi-
lized PEG spacer (RGB-286792) served as control.
CDK9 IP-Kinase Assays
Subconfluent plates of PC-3 cells (ATCC) were lysed in 4 ml RIPA
buffer (20 mM Tris-HCl [pH 8.0], 0.5% Nonidet P-40, 1% Triton X-
100, 150 mM KCl, 5 mM dithiothreitol) containing protease and pho-
phatase inhibitors (Roche). Lysates were clarified by centrifugation
and subsequently precleared by 30 min of incubation with Protein A
sepharose (CL4B) beads. Lysates were then incubated with mouse
anti-human CDK9 monoclonal antibody for 2 hr at 4ºC. The antigen-
antibody complex was precipitated by incubation with Protein A se-
pharose (CL4B) beads (Amersham Bioscience Corp. 17-0780-01) for
1 hr at 4ºC. The beads were pelleted and washed 5 times in 1 M KCl
wash buffer (20 mM Tris-HCl [pH 8.0], 0.5% Nonidet P-40, 1% Triton
X-100, 1 M KCl), once in assay buffer, then resuspended in assay
buffer (20 mM Tris-HCl [pH 8.0], 5 mM MgCl2, 60 mM NaCl) and ali-
quoted into 96-well plates. Compounds were dissolved in DMSO,
diluted into assay buffer lacking ATP (final DMSO is less then
0.1%), and preincubated for 20 min with CDK9 captured on sephar-
ose beads. CDK9 autophosphorylation, cyclin T1 crossphosphory-
lation, or GST-CTD3 (w2 mg per sample) phosphorylation
reactions were started by addition of ATP to the reaction mixtures
(final concentration: 10 mM ATP and 10 mCi 33P-ATP). The phosphor-
ylation reactions were stopped after 15 min at 37ºC by addition of
SDS-PAGE loading buffer and heating of the sample to 96ºC. The
samples were then analyzed by 4%–12% SDS-PAGE followed
by blotting onto nitrocellulose (BIO-RAD Laboratories, 162-0233)
membrane. Phosphorylation was detected on a Fuji Bas-5000
b-imager.
For detection of CDK9 and cyclin T1 by immunoblotting, the
membrane was incubated with mouse anti-human CDK9 or goat
anti-human cyclin T1 (SC-8127 Santa Cruz Biotechnology, Inc.),
followed by incubation with anti-mouse or goat HRP-conjugated
secondary antibody. Signals were detected by using ECL (Amer-
sham Biosciences Corp.) and autoradiography.
Effects of RGB-286147 on Cell Cycle Proteins in Intact Cells
HCT116 cells were treated with RGB-286147 (100 nM) for 24 hr.
Cells (adherent as well as floating cells) were collected. Lysis was
performed following a protocol adapted from Romero et al. [50],
and cell extracts were stored at 280ºC. Immunoblot analysis of
cell lysates was performed by using antibodies as indicated. Immu-
noblots were blotted with an anti-actin antibody as a loading con-
trol. Antibodies that were used were specific for: CDK2 (32 kDa),
P-Thr160-CDK2 (32 kDa), cyclin A (60 kDa), Rb (110 kDa),
P-Ser780-Rb, P-Ser795-Rb, and P-Ser807/811-Rb. The effect on
PARP cleavage was analyzed as follows: HCT116 cells were treated
with 100 nM RGB-286147 for 48 hr and compared to untreated cells.
PARP (116 kDa) and its cleaved form (89 kDa) were detected by
using a PARP-specific antibody.
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The following primary antibodies were used in this study: anti-actin
(I-19), anti-CDK5 (DC 17), anti-CDK9 (D-7), anti-CDK1 (17), and anti-
CDK7 (C-14) were from Santa Cruz; anti-P-CDK2 (Thr160), anti-
cyclin D1 (DCS6), anti-PARP, anti-P-Rb (Ser780), anti-P-Rb
(Ser795), anti-P-Rb (Ser807/811), and anti-Rb (4H1) were from Cell
Signaling; anti-cyclin A (25) and anti-CDK2 (55) were from BD Trans-
duction Laboratories; and anti-c-myc (9E10) was from Roche. The
secondary antibodies were from Zytomed (goat anti-rabbit IgG-
HRP and rabbit anti-goat IgG-HRP), Sigma (goat anti-mouse IgG-
HRP), and Amersham (sheep anti-mouse IgG-HRP).
Supplemental Data
Supplemental Data including details on MFC chemical synthesis
and antiproliferative effects of RGB-286147 in various human tumor
cell lines are available at http://www.chembiol.com/cgi/content/full/
12/10/1103/DC1/.
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